Humana Inc. (NYSE:HUM) Given Average Recommendation of “Hold” by Analysts

Humana Inc. (NYSE:HUM) has earned an average rating of “Hold” from the twenty-six brokerages that are covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a sell recommendation, fourteen have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $238.2917.

Several research firms recently weighed in on HUM. Morgan Stanley set a $146.00 price objective on Humana in a research note on Thursday. Wolfe Research raised their price target on Humana from $300.00 to $325.00 and gave the company an “outperform” rating in a research report on Thursday, January 8th. Barclays reiterated an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Cantor Fitzgerald dropped their target price on shares of Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a report on Thursday. Finally, Wells Fargo & Company downgraded shares of Humana from an “overweight” rating to a “cautious” rating in a report on Wednesday, January 7th.

Institutional Trading of Humana

A number of large investors have recently made changes to their positions in HUM. Vanguard Group Inc. boosted its stake in shares of Humana by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider’s stock worth $3,652,890,000 after purchasing an additional 106,030 shares during the last quarter. Dodge & Cox raised its holdings in Humana by 5.6% in the 2nd quarter. Dodge & Cox now owns 11,352,920 shares of the insurance provider’s stock valued at $2,775,562,000 after acquiring an additional 597,705 shares during the last quarter. Capital International Investors raised its holdings in Humana by 113.9% in the 4th quarter. Capital International Investors now owns 5,818,008 shares of the insurance provider’s stock valued at $1,490,239,000 after acquiring an additional 3,097,571 shares during the last quarter. State Street Corp boosted its holdings in shares of Humana by 1.8% during the fourth quarter. State Street Corp now owns 5,462,549 shares of the insurance provider’s stock worth $1,403,877,000 after purchasing an additional 97,211 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its position in shares of Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider’s stock valued at $1,151,759,000 after purchasing an additional 1,008,514 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Stock Up 2.8%

Humana stock opened at $183.92 on Monday. The stock’s 50 day moving average price is $244.65 and its 200 day moving average price is $261.02. Humana has a 1-year low of $169.61 and a 1-year high of $315.35. The company has a market cap of $22.12 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 1.96 and a beta of 0.44. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02.

Humana (NYSE:HUM) last released its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) EPS for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.Humana’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, sell-side analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.